B27 - in vitro screening mpox and ectromelia viruses
Active Awarded Last action
- Contract number
- 75N93026F00002
- Awardee
-
Utah State University UEI SPE2YDWHDYU4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $66,348
Award facts
- Contract value 29% obligated
-
- $66,347.70 Current, with exercised options
- $227,326.49 Potential, with all options
- Completion date 97% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Logan, UT 84322, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $66,348 |
About this award
Utah State University was awarded a delivery order valued at $227,326.49 under the In Vitro Assessments of Antimicrobial Activity (IVAAA) program, a $146.3 million indefinite delivery vehicle administered by the National Institute of Allergy and Infectious Diseases (NIAID). This delivery order, designated B27, supports in vitro screening of mpox and ectromelia viruses and will be performed in Logan, Utah with an ultimate completion date of January 14, 2027. The contract employs a firm fixed-price structure with no set-aside designation, reflecting USU's status as a qualified institutional contractor capable of delivering specialized infectious disease research and diagnostic services at the federal level.
The award represents USU's continued role in NIAID's infectious disease research mission, which prioritizes the development and evaluation of countermeasures including vaccines, therapeutics, and diagnostics against priority pathogens with pandemic potential. USU's comprehensive capabilities in viral screening, specialized reagent generation, and laboratory analysis services position the institution as a critical partner in national biodefense and public health preparedness initiatives. This delivery order builds upon USU's existing $653,618.00 in prior IVAAA program obligations and complements its substantial $146.3 million primary indefinite delivery contract with NIAID focused on pre-clinical models of infectious diseases.
Quick answers
Who was awarded contract 75N93026F00002?
75N93026F00002 was awarded to Utah State University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 15, 2019.
How much is contract 75N93026F00002 worth?
The government has obligated $66,348 on 75N93026F00002. Its potential value, with all options, is $227,326.
Is contract 75N93026F00002 an order under another contract?
Yes. 75N93026F00002 is a delivery order under 75N93019D00021, an indefinite delivery contract, on In Vitro Assessments of Antimicrobial Activity (IVAAA).
Was contract 75N93026F00002 competed?
The extent of competition for 75N93026F00002 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award